Established within the Sanford Research in 2011 as a part of NIH COBRE-supported (1P20RR024219- 01A2 grant) Cancer Biology Research Center, the Flow Cytometry Core maintains and supports numerous flow cytometric units designed to perform multiple cell phenotyping and characterization analyses, as well as to execute cell sorting/separation protocols. The Core delivers to its users a variety of modern flow cytometry applications and analyses. The Core also houses data analysis stations with software suits such as CellQuest, FlowJo and others, and offers comprehensive training on all its equipment. The Core is currently additionally supported by Sanford Research, and actively assists with the projects facilitated by Cancer Biology Research Center Project Leaders, other Sanford Research faculty, and by principle investigators from neighboring institutions. With Sanford Research's strong commitment to excellence in biomedical research and a consequent growth in research laboratories, the demand for Flow Cytometry Core services has exponentially growing over the last several years. As Sanford Research continues to expand into areas of basic biomedical sciences, so does our need for the state-of-the-art flow cytometry capabilities. The objective of the current application is to secure the continuation of the Core's operations, to augment and enhance Core's capabilities, while providing continuous support of the Cancer Biology Research Center. Accordingly, we propose that the Flow Cytometry Core will continue delivering quality services to all five Project Leaders of the current COBRE renewal proposal, as well as other investigators at Sanford Research, and neighboring institutions. We also intent to develop a fee-for service structure, providing for Core's self-sustainability at the end of the grant support. To achieve the above-stated objective, the following Specific Aims are proposed: 1. To continue support the flow cytometric needs of the COBRE Project Leaders and Sanford Research faculty. The Flow Cytometry Core provides investigators with on-site flow cytometry services and support, decreasing hands-on time and allowing for direct communication between investigators and Core staff. 2. To educate on novel applications; assist with efficient experimental design; help with manuscript preparation, and funding applications. Core staff personally interacts with investigators and their lab staff on all above subjects. 3. To enhance the Flow Cytometry Core infrastructure. The Flow Cytometry Core will add to its staff a new Postdoctoral Fellow who will be responsible for the direct methodological development, and implementation of flow cytometry-based experimental strategies pertinent to the specific research plans of COBRE Project Leaders, as well as for monitoring and implementing a new developments in flow cytometric methoodology. 4. To create a sustainable Flow Cytometry Core. Jointly with Sanford Research Shared Resources Committee we will develop a fee-for-service structure, allowing Core's sustainability beyond the COBRE funding period.

Public Health Relevance

The Flow Cytometry Core provides continuous support of Flow Cytometry instruments, and offers expertise in cell analysis/sorting techniques for the Sanford Research faculty. The major services provided by the Flow Cytometry Core are design, troubleshooting and execution of complex flow cytometry-based approaches, which address the experimental questions of the Project Leaders. The Flow Cytometry Core also routinely performs data processing and implements multiple analyses of experimental data. All these services will be maintained and enhanced to ensure the successful execution of the research project proposed by the Project Leaders of the current application.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
5P20GM103548-08
Application #
9517934
Study Section
Special Emphasis Panel (ZGM1)
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
8
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Sanford Research/Usd
Department
Type
DUNS #
050113252
City
Sioux Falls
State
SD
Country
United States
Zip Code
57104
Anderson, Ruthellen H; Lensing, Cody J; Forred, Benjamin J et al. (2018) Differentiating Antiproliferative and Chemopreventive Modes of Activity for Electron-Deficient Aryl Isothiocyanates against Human MCF-7 Cells. ChemMedChem 13:1695-1710
Johnson, Tyler B; Mechels, Keegan; Anderson, Ruth Ellen et al. (2018) Characterization of a recurrent missense mutation in the forkhead DNA-binding domain of FOXP1. Sci Rep 8:16161
Butler, Merlin G; Hossain, Waheeda A; Tessman, Robert et al. (2018) Preliminary observations of mitochondrial dysfunction in Prader-Willi syndrome. Am J Med Genet A 176:2587-2594
Sane, Sanam; Hafner, Andre; Srinivasan, Rekha et al. (2018) UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortalin-2 in cancer cells. Mol Oncol 12:1753-1777
Anderson, Ruthellen H; Kerkvliet, Jason G; Otta, Jaelin J et al. (2018) Generation of a CLTA reporter human induced pluripotent stem cell line, CRMi001-A-1, using the CRISPR/Cas9 system to monitor endogenous clathrin trafficking. Stem Cell Res 33:95-99
Lucido, Christopher T; Callejas-Valera, Juan L; Colbert, Paul L et al. (2018) ?2-Adrenergic receptor modulates mitochondrial metabolism and disease progression in recurrent/metastatic HPV(+) HNSCC. Oncogenesis 7:81
Miszuk, Jacob M; Xu, Tao; Yao, Qingqing et al. (2018) Functionalization of PCL-3D Electrospun Nanofibrous Scaffolds for Improved BMP2-Induced Bone Formation. Appl Mater Today 10:194-202
Anderson, Ruthellen H; Francis, Kevin R (2018) Modeling rare diseases with induced pluripotent stem cell technology. Mol Cell Probes 40:52-59
Amatya, Christina; Radichev, Ilian A; Ellefson, Jacob et al. (2018) Self-Transducible Bimodal PDX1-FOXP3 Protein Lifts Insulin Secretion and Curbs Autoimmunity, Boosting Tregs in Type 1 Diabetic Mice. Mol Ther 26:184-198
Yao, Qingqing; Liu, Yangxi; Selvaratnam, Balaranjan et al. (2018) Mesoporous silicate nanoparticles/3D nanofibrous scaffold-mediated dual-drug delivery for bone tissue engineering. J Control Release 279:69-78

Showing the most recent 10 out of 71 publications